India, July 22 -- Shares of Medpace Holdings Inc. (MEDP) are up over 40% in premarket trading Tuesday, following strong financial results for the second quarter ended June 30, 2025, and rosy outlook for the year.
The company is a global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.
Q2 Scorecard
On a GAAP basis, net income for the second quarter of 2025 increased to $90.3 million, or $3.10 per share, from $88.4 million, or $2.75 per share, in the year-ago period.
Revenue for Q2, 2025 jumped 14.2% to $603.3 million from $528.1 million in Q2, 2024.
Cash and cash equivalents were $46.3 million on June 30, 202...